Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s):  MEDXF

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.


TSX:MDP - Post by User

Bullboard Posts
Comment by STOCKMAN70on Aug 14, 2016 10:03pm
189 Views
Post# 25140898

RE:RE:Piling up.

RE:RE:Piling up.I saw that as well and agree that it will be hard for this go much above .25c for a while as GUD sells shares (they have many days of avg volume worth). I had a position and sold at .29 and .265. Would look to get back in at some point. 

I am not sure how I feel about knight selling their PDP shares just after they receive them. I can see from the point that they are getting good returns for their own shareholders but from the point of supporting PDP and other companies who they are investing in - in a way they are hurting the share price and shareholders of PDP and not sure if that would have a negative effect for other small companies who would potentially do a stock deal with knight going forward. At this point it seems like knight got a much better bargain than PDP; If they did the deal today PDP would have received a lot more knight shares in exchange. With that said having knight doing the deal with PDP does offer more credibility to PDP which does help PDP and its shareholders.  
Bullboard Posts